ArticleTherapeutic advances in endocrinology and metabolism2025
Global epidemiology and burden of type 2 diabetes in adults aged 55 and older: insights from 1990 to 2021.
Article in Therapeutic advances in endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Article
- From metabolites to membrane vesicles: Unifying gut microbial signals in obesity, t2dm, and MASLD.World journal of microbiology & biotechnology · 2026Review
- Toward fully algorithmic care for type 1 diabetes: The case for AI autonomy, and a recalibrated role for the diabetologist in an ageing type 2 diabetes population.PLOS digital health · 2026Article
- Risk of Diabetes Mellitus and Its Association with Cardiorespiratory Endurance in Zenú Indigenous People in Momil, Córdoba, Colombia.International journal of environmental research and public health · 2026Article
- Association of Type 2 Diabetes Mellitus With Dietary Vitamin B12 Intake in Individuals With Different Fat Mass and Obesity-Associated (FTO) Genotypes.Food science & nutrition · 2026Article
- Epidemiological trends and burden of gout in China and the European Union: a GBD 2023 and Mendelian randomization study.Clinical rheumatology · 2026Article
- Comorbidities in Age-Related Cataract: Epidemiological Burden and Public Health Implications.Vision (Basel, Switzerland) · 2026Review
- Structural and morphological dynamics of "on-path" and "off-path" oligomers of human islet amyloid polypeptide.Protein science : a publication of the Protein Society · 2026Article
- Association Between Vitamin D Deficiency and Cardiometabolic Risk Clustering Among Rural Community-Dwelling Older Adults: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Global Mortality and Disability-Adjusted Life Years Attributable to Tobacco Exposure Among Middle-Aged and Older Adults With Type 2 Diabetes, 1990-2021: A Systematic Analysis of GBD 2021 Data With Projections to 2042.Journal of diabetes research · 2026Article
- Olink proteomics identifies serum protein biomarkers and an age-stratified diagnostic model for diabetes in Chinese patients.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) poses a growing global health challenge, particularly among individuals aged 55 years and above, placing significant pressure on healthcare systems. Objectives: This study aims to assess long-term trends in T2DM burden and its risk factors in this demographic from 1990 to 2021. Design: We conducted a retrospective analysis of T2DM based on the latest 2021 Global Burden of Disease (GBD) database. Methods: Utilizing data from the 2021 GBD Study, we analyzed T2DM incidence, prevalence, and disability-adjusted life years (DALYs) among individuals aged ⩾55 years, stratified by sex and age group. An autoregressive integrated moving average model was applied to forecast trends for 2022-2036. Results: In 2021, there were 9,179,347 (95% uncertainty interval (UI), 7,905,452-10,626,325) T2DM cases among those aged 55 years and above. From 1990 to 2021, global incidence increased from 409.06 (95% UI, 349.86-477.48) to 617.73 (95% UI, 532.00-715.10) per 100,000 population; diabetes-related mortality rose from 81.55 (95% UI, 76.57-85.44) to 96.19 (95% UI, 88.62-102.11) per 100,000, and DALYs climbed from 2562.71 (95% UI, 2293.81-2926.77) to 3552.41 (95% UI, 3041.94-4200.97) per 100,000. The highest mortality increase was in low-middle sociodemographic index (SDI) regions, while high SDI regions saw declines. Eastern Europe reported the highest incidence rate among 21 regions, at 1218.43 per 100,000 (95% UI, 1083.02-1370.82). Environmental, occupational, and behavioral risks were major contributors to diabetes-related mortality in this age group. Projections estimate T2DM cases will rise from 9.3 million in 2022 to 12.3 million by 2036. Conclusion: The global burden of diabetes in adults aged ⩾55 years has risen substantially from 1990 to 2021. As the population continues to age, urgent action is needed to address this growing disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.